Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Core Scientific Inc (CORZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Core Scientific Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Core Scientific Inc trades at $23.09 (market cap $7.47B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.3× Core Scientific Inc's market cap, and Core Scientific Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CORZ | |
|---|---|---|
Market Cap | $39.89B | $7.47B |
Sector | Health | Technology |
52-Week High | $491.22 | $29.16 |
52-Week Low | $278.09 | $12.51 |
Enterprise Value | $38.15B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CORZ trades at $23.49, down 1.05% on the day, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue growth driven by AI colocation, yet missed EPS estimates. Strong analyst support exists with 19 buy ratings and a $34.17 consensus target, indicating 45% upside potential.
Outlook remains optimistic due to strategic pivot to AI infrastructure, though significant risks include persistent losses, high cash burn, and execution challenges in scaling data center operations amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →
